![]() |
|
|
Vol. 283, Issue 3, 1009-1017, 1997
Department of Psychology, University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina
The purpose of this investigation was to evaluate the discriminative
stimulus effects of the mixed-opioid agonist/antagonist dezocine. In
pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a
series of opioids with activity at the mu opioid receptor substituted completely for the dezocine stimulus with a rank
order of potency similar to that obtained in other assays sensitive to
the effects of mu agonists (i.e., fentanyl
>[-]-cyclazocine >buprenorphine = butorphanol
>l-methadone >nalbuphine >[-]-metazocine >morphine). (-)-N-allylnormetazocine and (+)-propoxyphene substituted partially for the dezocine stimulus, an effect obtained even when tested up to doses that suppressed responding. Naloxone (0.1 - 10 mg/kg) antagonized the stimulus effects of dezocine, (+)-propoxyphene and fentanyl in a dose-related manner, whereas doses of naloxone that
antagonized fentanyl's rate-decreasing effects failed to antagonize
the rate-decreasing effects of dezocine and (+)-propoxyphene. A
10-mg/kg dose of the mu-selective, noncompetitive
antagonist
-funaltrexamine was more effective against the stimulus
effects of dezocine and nalbuphine than against morphine and fentanyl. As was observed with naloxone,
-funaltrexamine failed to antagonize dezocine's rate-decreasing effects. The delta agonists
BW373U86 and SNC80 substituted partially for the dezocine stimulus, and these effects were reversed by doses of the delta-selective antagonist naltrindole (0.1 and 1.0 mg/kg) that had no effect on the dezocine stimulus. Naltrindole also antagonized the rate-decreasing effects produced by BW373U86 and SNC80, but not those of dezocine. The kappa agonists bremazocine, spiradoline, U50,488 and
U69,593 failed to substitute for the dezocine stimulus. The
kappa-selective antagonist norbinaltorphimine (1.0 mg/kg) failed to antagonize dezocine's stimulus or rate-decreasing
effects. The present findings indicate that dezocine shares similar
stimulus effects with both mu and delta
agonists, its stimulus effects are reversed by
mu-selective antagonists, and its rate-decreasing
effects are not mediated by activity at mu,
kappa or delta opioid receptors.
This article has been cited by other articles:
![]() |
E. A. Walker, M. J. Picker, A. Granger, and L. A. Dykstra Effects of Opioids in Morphine-Treated Pigeons Trained to Discriminate among Morphine, the Low-Efficacy Agonist Nalbuphine, and Saline J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 150 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Walker and A. M. Young Clocinnamox Distinguishes Opioid Agonists According to Relative Efficacy in Normal and Morphine-Treated Rats Trained to Discriminate Morphine J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 101 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text] |
||||
![]() |
M. R. Brandt, S. S. Negus, N. K. Mello, M. S. Furness, X. Zhang, and K. C. Rice Discriminative Stimulus Effects of the Nonpeptidic delta -Opioid Agonist SNC80 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1157 - 1164. [Abstract] [Full Text] |
||||